Technology
Dimerix unveils ‘tremendous’ top-line results for lead drug in treating rare kidney disorder – Small Caps
Drug development company Dimerix (ASX: DXB) emerged from a trading halt today with top-line results from its phase 2a ACTION study into DMX-200 for treatment of focal segmental glomerulosclerosis (FSGS), a rare kidney disorder that often leads to end-stage ki…
Drug development company Dimerix (ASX: DXB) emerged from a trading halt today with top-line results from its phase 2a ACTION study into DMX-200 for treatment of focal segmental glomerulosclerosis (FSGS), a rare kidney disorder that often leads to end-stage kidney failure.
Dimerix received orphan drug designation for DMX-200 in November 2018 in both the US and Europe for the treatment of FSGS, after repurposing the drug based on preliminary non-clinical data which showed a reduction in the numbe…
-
Noosa News16 hours agoSunshine Coast locals raise $24,000 to rescue children from trafficking
-
Noosa News16 hours agoJack Steele stunned by how many Noosa kids are riding $3000 e-bikes
-
Noosa News14 hours agoIndustry warns building houses in Australia slower than it was a decade ago, construction targets missed
-
Noosa News3 hours agoWoman rescued from car on Samford Road, Ferny Hills